- Trials with a EudraCT protocol (10,509)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10,509 result(s) found for: Blood Disease.
Displaying page 447 of 526.
EudraCT Number: 2018-000240-26 | Sponsor Protocol Number: PC_ASP_002 | Start Date*: 2019-05-17 | |||||||||||
Sponsor Name:Pulmocide Ltd | |||||||||||||
Full Title: An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipi... | |||||||||||||
Medical condition: Pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000678-19 | Sponsor Protocol Number: MCL2008-01 | Start Date*: 2010-08-05 | ||||||||||||||||
Sponsor Name:Klinikum der Universität München, Klinikum Großhadern | ||||||||||||||||||
Full Title: Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network | ||||||||||||||||||
Medical condition: patients with relapsed or refractory mantle cell lymphoma after or not eligible for myeloablative treatment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005542-56 | Sponsor Protocol Number: ESR-15-10870 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:Copenhagen University Hospital Bispebjerg | |||||||||||||
Full Title: Effects of anti-TSLP on airway hyperresponsiveness and mast cell phenotype in asthma - A randomized double-blind, placebo-controlled trial of MEDI9929 The UPSTREAM study | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001641-40 | Sponsor Protocol Number: ESR-17-12933 | Start Date*: 2019-09-09 | ||||||||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | ||||||||||||||||||
Full Title: Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study | ||||||||||||||||||
Medical condition: Advanced resectable head and neck tumor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004457-24 | Sponsor Protocol Number: PREDIX-II-HER2 | Start Date*: 2019-03-06 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: PREDIX II HER2. Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer Part of a platform of translational phase 2 trials based on mole... | ||
Medical condition: Primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002686-19 | Sponsor Protocol Number: 2018-HJEPharma-001 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest | |||||||||||||
Medical condition: We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-h... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003271-35 | Sponsor Protocol Number: KU-AIM-01-2018 | Start Date*: 2019-01-07 | |||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||
Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS | |||||||||||||
Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002462-35 | Sponsor Protocol Number: NN5401-1792 | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metf... | |||||||||||||
Medical condition: type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002793-23 | Sponsor Protocol Number: AI444-042 | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Evaluation of Daclatasvir (BMS-790052) in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4 Revised Protocol Number ... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002203-34 | Sponsor Protocol Number: M16-813 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:AbbVie Deutschland | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003299-15 | Sponsor Protocol Number: METFORAGING | Start Date*: 2021-10-19 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital La Paz | ||
Full Title: A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living wi... | ||
Medical condition: Patients with HIV and accelerated biological aging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000454-38 | Sponsor Protocol Number: CPDR001X2201 | Start Date*: 2015-10-13 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progr... | ||
Medical condition: Moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003295-10 | Sponsor Protocol Number: C0524T05 | Start Date*: 2006-05-17 |
Sponsor Name:Centocor BV | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Acti... | ||
Medical condition: Active Rheumatoid Arthritis (methotrexate [MTX]-naïve) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001602-16 | Sponsor Protocol Number: 25706 | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Effects of Insulin Levemir and Insulin Insulatard on renal handling of sodium, fluid retention and weight in type 2 diabetic patients | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005254-53 | Sponsor Protocol Number: BKOS-03 | Start Date*: 2012-05-14 | |||||||||||
Sponsor Name:Menarini Ricerche S.p.A | |||||||||||||
Full Title: A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasi... | |||||||||||||
Medical condition: Ostoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004235-39 | Sponsor Protocol Number: 20140929sketamine | Start Date*: 2016-08-06 | |||||||||||||||||||||
Sponsor Name:Folktandvården, Landstinget Dalarna | |||||||||||||||||||||||
Full Title: Pain control in surgical intervention. Biomarkers in acute and chronical post operative pain | |||||||||||||||||||||||
Medical condition: Post operative pain | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005732-28 | Sponsor Protocol Number: LE-9999-401-BE | Start Date*: 2013-06-14 | ||||||||||||||||
Sponsor Name:Takeda Belgium | ||||||||||||||||||
Full Title: A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total... | ||||||||||||||||||
Medical condition: Patient that underwent a near total thyroidectomy and therefore are compelled to take levothyroxine hormone substition therapy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006697-15 | Sponsor Protocol Number: D3560L00068 | Start Date*: 2007-03-27 | |||||||||||
Sponsor Name:AstraZeneca SAS | |||||||||||||
Full Title: Evaluation de l'efficacité et de la tolérance de rosuvastatine 5 mg versus pravastatine 40 mg et atorvastatine 10 mg chez des patients hypercholestérolémiques de type IIa et IIb | |||||||||||||
Medical condition: Hypercholestérolémies de type IIa et IIb | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005633-10 | Sponsor Protocol Number: DORI INI 2002 | Start Date*: 2008-01-24 | ||||||||||||||||
Sponsor Name:ORTHO MCNEIL JANSSEN SCIENTIFIC AFFAIRS, LLC | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals where Pseudomonas aeruginosa may be a Prevalent Pathogen. | ||||||||||||||||||
Medical condition: Nosocomial and Ventilator-Associated Pneumonia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-009936-56 | Sponsor Protocol Number: ACT10775 | Start Date*: 2009-05-11 | |||||||||||
Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
Full Title: Randomized, double-blind, placebo and active controlled study of the activity of SAR407899A single-dose on the ability to increase duration of penile rigidity, under experimental condition, in pati... | |||||||||||||
Medical condition: Mild to moderate erectile dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
